Malignancy as a comorbidity in rheumatic diseases

Carl Turesson, Eric Lawrence Matteson

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.

Original languageEnglish (US)
Article numberkes189
Pages (from-to)5-14
Number of pages10
JournalRheumatology (United Kingdom)
Volume52
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Rheumatic Diseases
Comorbidity
Neoplasms
Myositis
Immunomodulation
Environmental Exposure
Virus Diseases
Life Expectancy
Autoimmune Diseases
Smoking
Quality of Life
Therapeutics

Keywords

  • Cancer
  • Comorbidity
  • Malignancy
  • Mortality
  • Myositis
  • RA
  • Rheumatic disease
  • Risk factors
  • SS
  • Treatment SLE

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Malignancy as a comorbidity in rheumatic diseases. / Turesson, Carl; Matteson, Eric Lawrence.

In: Rheumatology (United Kingdom), Vol. 52, No. 1, kes189, 01.2013, p. 5-14.

Research output: Contribution to journalArticle

@article{e1a7cd30044b4369bc628789e0299141,
title = "Malignancy as a comorbidity in rheumatic diseases",
abstract = "Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.",
keywords = "Cancer, Comorbidity, Malignancy, Mortality, Myositis, RA, Rheumatic disease, Risk factors, SS, Treatment SLE",
author = "Carl Turesson and Matteson, {Eric Lawrence}",
year = "2013",
month = "1",
doi = "10.1093/rheumatology/kes189",
language = "English (US)",
volume = "52",
pages = "5--14",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Malignancy as a comorbidity in rheumatic diseases

AU - Turesson, Carl

AU - Matteson, Eric Lawrence

PY - 2013/1

Y1 - 2013/1

N2 - Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.

AB - Patients with systemic autoimmune rheumatic diseases, particularly RA, SLE, SS and idiopathic inflammatory myopathies, are at increased risk of developing malignancies. Cancer occurrence adds to the disease burden in these patients, adversely affecting quality of life and life expectancy. This risk is related to the pathobiology of the underlying rheumatic disease including the inflammatory burden, immunological defects, and personal and environmental exposure such as smoking and some viral infections. Immunomodulatory therapies, especially chemotherapeutic agents, are also associated with an increased risk of cancer in these conditions. The decision to use immunomodulating therapies in patients with rheumatic disease must take into account the disease severity, expectations for disease control, comorbidities and host and environmental risk factors for cancer. Effective screening and monitoring strategies are important in reducing the risk of cancer in these patients.

KW - Cancer

KW - Comorbidity

KW - Malignancy

KW - Mortality

KW - Myositis

KW - RA

KW - Rheumatic disease

KW - Risk factors

KW - SS

KW - Treatment SLE

UR - http://www.scopus.com/inward/record.url?scp=84871146837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871146837&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kes189

DO - 10.1093/rheumatology/kes189

M3 - Article

C2 - 22829694

AN - SCOPUS:84871146837

VL - 52

SP - 5

EP - 14

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 1

M1 - kes189

ER -